Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
University Library
Adelaide Festival of Ideas
Barr Smith Press
Friends of the University of Adelaide Library
Library Publications
Internal documents (Library staff only)
Library images
Library reports and papers
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 1-10 of 23 (Search time: 0.005 seconds).
previous
1
2
3
next
Item hits:
Preview
Issue Date
Title
Author(s)
2006
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Druker, B.
;
Guilhot, F.
;
O'Brien, S.
;
Gathmann, I.
;
Kantarjian, H.
;
Gattermann, N.
;
Deininger, M.
;
Silver, R.
;
Goldman, J.
;
Stone, R.
;
Cervantes, F.
;
Hochhaus, A.
;
Powell, B.
;
Gabrilove, J.
;
Rousselot, P.
;
Reiffers, J.
;
Cornelissen, J.
;
Hughes, T.
;
Agis, H.
;
Fischer, T.
;
et al.
2014
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily
Hughes, T.
;
Hochhaus, A.
;
Kantarjian, H.
;
Cervantes, F.
;
Guilhot, F.
;
Niederwieser, D.
;
Le Coutre, P.
;
Rosti, G.
;
Ossenkoppele, G.
;
Lobo, C.
;
Shibayama, H.
;
Fan, X.
;
Menssen, H.
;
Kemp, C.
;
Larson, R.
;
Saglio, G.
2013
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
Ross, D.
;
Branford, S.
;
Seymour, J.
;
Schwarer, A.
;
Arthur, C.
;
Yeung, D.
;
Dang, P.
;
Goyne, J.
;
Slader, C.
;
Filshie, R.
;
Mills, A.
;
Vaz de Melo, J.
;
White, D.
;
Grigg, A.
;
Hughes, T.
2013
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M.
;
Deininger, M.
;
Rosti, G.
;
Hochhaus, A.
;
Soverini, S.
;
Apperley, J.
;
Cervantes, F.
;
Clark, R.
;
Cortes, J.
;
Guilhot, F.
;
Hansen-Hjorth, H.
;
Hughes, T.
;
Kantarjian, H.
;
Kim, D.
;
Larson, R.
;
Lipton, J.
;
Mahon, F.
;
Martinelli, G.
;
Mayer, J.
;
Muller, M.
;
et al.
2013
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy
Angelini, S.
;
Soverini, S.
;
Ravegnini, G.
;
Barnett, M.
;
Turrini, E.
;
Thornquist, M.
;
Pane, F.
;
Hughes, T.
;
White, D.
;
Radich, J.
;
Kim, D.
;
Saglio, G.
;
Cilloni, D.
;
Iacobucci, I.
;
Perini, G.
;
Woodman, R.
;
Cantelli-Forti, G.
;
Baccarani, M.
;
Hrelia, P.
;
Martinelli, G.
2005
Dynamics of chronic myeloid leukaemia
Michor, F.
;
Hughes, T.
;
Iwasa, Y.
;
Branford, S.
;
Shah, N.
;
Sawyers, C.
;
Nowak, M.
2011
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
Kantarjian, H.
;
Hochhaus, A.
;
Saglio, G.
;
de Souza, C.
;
Flinn, I.
;
Stenke, L.
;
Goh, Y.
;
Rosti, G.
;
Nakamae, H.
;
Gallagher, N.
;
Hoenekopp, A.
;
Blakesley, R.
;
Larson, R.
;
Hughes, T.
2003
Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR
Hui, C.
;
Goh, K.
;
White, D.
;
Branford, S.
;
Grigg, A.
;
Seymour, J.
;
Kwan, Y.
;
Walsh, S.
;
Hoyt, R.
;
Trickett, A.
;
Rudzki, Z.
;
Ma, D.
;
To, L.
;
Hughes, T.
2010
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
Hughes, T.
;
Hochhaus, A.
;
Branford, S.
;
Muller, M.
;
Kaeda, J.
;
Foroni, L.
;
Druker, B.
;
Guilhot, F.
;
Larson, R.
;
O'Brien, S.
;
Rudoltz, M.
;
Mone, M.
;
Wehrle, E.
;
Modur, V.
;
Goldman, J.
;
Radich, J.
2009
Impact of baseline BCR-ABL mutations on response to Nilotinib in patients with chronic myeloid leukemia in chronic phase
Hughes, T.
;
Saglio, G.
;
Branford, S.
;
Soverini, S.
;
Kim, J.
;
Muller, M.
;
Martinelli, G.
;
Cortes, J.
;
Beppu, L.
;
Gottardi, E.
;
Dongho, K.
;
Erben, P.
;
Shou, Y.
;
Haque, A.
;
Gallagher, N.
;
Radich, J.
;
Hochhaus, A.
Discover
Author
11
Branford, S.
10
Hochhaus, A.
9
Kantarjian, H.
8
White, D.
7
Larson, R.
7
Radich, J.
7
Saglio, G.
6
Cortes, J.
6
Guilhot, F.
6
Kim, D.
.
next >
Subject
23
Humans
23
Pyrimidines
22
Benzamides
22
Piperazines
19
Leukemia, Myelogenous, Chronic, B...
18
Antineoplastic Agents
11
Protein Kinase Inhibitors
10
Female
10
Fusion Proteins, bcr-abl
10
Male
.
next >
Date issued
15
2010 - 2017
8
2003 - 2009